2023 | | A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19 | 허중연 |
2021 | | Clinical and Laboratory Factors Associated with Symptom Development in Asymptomatic COVID-19 Patients at the Time of Diagnosis | 김은진, 신승수 |
2021 | | Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study | 허중연 |
2023 | | Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials | 허중연 |
2022 | | Clinical findings, viral load, and outcomes of COVID-19: Comparison of patients with negative and positive initial chest computed tomography | 김은진, 신승수 |
2024 | | Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach | 현학준 |
2022 | | COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19 | 김영롱, 김은진, 허중연 |
2021 | | Effects of early corticosteroid use in patients with severe coronavirus disease 2019 | 김은진 |
2022 | | Encephalitis with status epilepticus and stroke as complications of non-severe COVID-19 in a young female patient: a case report | 고승연, 김태준, 최영화, 최준영 |
2024 | | Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy | 김영롱, 정근옥, 허중연 |
2023 | | Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection | 허중연 |
2022 | | Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study | 허중연 |
2023 | | Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial | 김은진, 허중연 |
2023 | | Impact of COVID-19 pandemic on healthcare-associated infections at intensive care units in South Korea: data from the Korean National Healthcare-Associated Infections Surveillance System (KONIS) | 김은진 |
2021 | | Implementation of the COVID-19 vulnerability index across an international network of health care data sets: Collaborative external validation study | 박래웅, 최영화 |
2020 | | Interim Guidelines on Antiviral Therapy for COVID-19 | 허중연 |
2021 | | Korean Society of infectious diseases/national evidence-based healthcare collaborating agency recommendations for anti-SARS-CoV-2 monoclonal antibody treatment of patients with COVID-19 | 허중연 |
2024 | | Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination | 현학준 |
2022 | | Maternal and Neonatal Outcomes in Pregnant Women With Coronavirus Disease 2019 in Korea | 김은진 |
2023 | | Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study | 허중연 |
2021 | | Revised Korean society of infectious diseases/national evidence-based healthcarea collaborating agency guidelines on the treatment of patients with COVID-19 | 허중연 |
2023 | | Risk of lymphadenopathy from SARS-CoV-2 vaccination in Korea: a self-controlled case series analysis | 허중연 |
2022 | | Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial | 허중연 |
2022 | | Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network | 박래웅, 최영화 |
2023 | | Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity | 허중연 |
2022 | | Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment | 김영롱, 유진세, 허중연 |